Aerocrine issues new shares and convertible bonds
Aerocrine AB (publ) carries out a SEK 225 million directed issue of new shares and convertible bonds to Danish Novo A/S, as well as a SEK 155.5 million rights issue.
Aerocrine is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases.
Aerocrine is being advised by Mannheimer Swartling on the transaction. The firm's team consists of Eva Hägg, Nils Nostell and Rasmus Fahlén.